World Water Day 2019 | Boehringer Ingelheim US
Click here to find out more on the steps Boehringer Ingelheim are taking on World Water Day 2019 to support animal shelters in Mexico City.
Search
BI initiates Study of Sequencing in EGFR Lung Cancer | BI US
Boehringer Ingelheim has initiated a real-world study to assess the impact of sequential therapy in patients with EGFR mutation-positive advanced NSCLC.
Partnering Days
Partnering Days
Real-world study shows sequencing of Gilotrif® followed by osimertinib delivered a combined median time on treatment of 27.6 months in patients with EGFR mutation-positive NSCLC
Real-world study shows sequencing of Gilotrif
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
Boehringer Ingelheim to Acquire Labor Dr. Merk & Kollegen to Strengthen its Next Generation Cancer Immunology Program
A day of giving back at Pegasus Therapeutic Riding
Take a look at our volunteer day spent refreshing a farm committed to equine therapy.
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Boehringer Ingelheim and Vanderbilt University Expand Partnership to Develop Novel Treatment Approaches for Cancer
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
Interview with Norbert Kraut: How cancer drives us forward
Norbert Kraut, our Global Head of Cancer Research at Boehringer Ingelheim, shares our approach to advancing cancer research and exploring new technologies
Innovation in Oncology and Cancer Immunology
Cancer research is one of the cornerstones of BI's research and has resulted in the launch of 2 products for the treatment of non-small cell lung cancer.
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Collaborates with Proxygen to Explore Molecular Glue Degraders - a Novel Approach to Fight Cancer
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim and MD Anderson Form Unique Virtual Research and Development Center to Rapidly Advance New Cancer Therapies
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim acquires Abexxa Biologics to further expand its research efforts in cancer immunology and novel immunotherapeutic approaches
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
Boehringer Ingelheim and Lilly Announce Clinical Trial Collaboration in Metastatic Breast Cancer
The power of patient advocacy in cancer care
Patients and advocacy organizations agree that patient empowerment is key to quality cancer care
Real-world analysis reinforces that Gilotrif® dose adjustments reduce the frequency and intensity of adverse drug reactions without impacting efficacy
dose adjustments reduce the frequency and intensity of adverse
Targeting HER2 in cancer
Our cancer researchers share insights into the discovery of our investigational HER2-selective tyrosine kinase inhibitor.
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical Stage MEK Inhibitor Compound
Boehringer Ingelheim Expands KRAS Cancer Program with Lupin’s Clinical
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Boehringer Ingelheim Acquires Northern Biologics’ Preclinical Cancer Antibody Pipeline, Expanding Immuno-oncology Portfolio
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim and Enara Bio Enter Strategic Collaboration and Licensing Agreement to Discover Novel Shared Antigens for Cancer Immunotherapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Why cancer care is personal for us
At Boehringer Ingelheim, we have made a generational commitment to transforming cancer care, with the ultimate goal of curing a range of cancers.
Cancer
Cancer